-
Pitfalls and Opportunities for the Growing Role of AI in Heart Failure J. Card. Fail. (IF 6.0) Pub Date : 2024-03-12 Jagpreet S. Grewal MD, Partho P. Sengupta MD
-
Synergy, not Silos: The Intersection of Medical and Surgical Training in Advanced Heart Failure J. Card. Fail. (IF 6.0) Pub Date : 2024-03-07 Jenna Skowronski MD, Alexander G Hajduczok MD, Laura DiChiacchio MDPhD
-
Capturing the evolving landscape of primary graft dysfunction after heart transplantation. Will Achilles ever overtake the tortoise? J. Card. Fail. (IF 6.0) Pub Date : 2024-03-07 Melana Yuzefpolskaya MD, Paolo C. Colombo MD
-
Unmasking HFpEF With Artificial Intelligence: A Disruptive Opportunity for Disease Detection J. Card. Fail. (IF 6.0) Pub Date : 2024-03-05 AMOGH KARNIK MD MSc, MADELINE JANKOWSKI RDCS, AKHIL NARANG MD
-
Obesity and Heart Failure: A New Era Begins J. Card. Fail. (IF 6.0) Pub Date : 2024-03-04 Barry A. Borlaug MD, Tammy L. Kindel MD PhD
-
Early Experience With Devices That Reduce Kidney Vascular Afterload From the Veins J. Card. Fail. (IF 6.0) Pub Date : 2024-03-04 ALEXANDER M. SPRING MD, ENKLAJD MARSELA MD, ULRICH P. JORDE MD
-
Contemporary Diuretic Therapies for Acute Heart Failure: Time for a Desalination-Guided Approach? J. Card. Fail. (IF 6.0) Pub Date : 2024-03-04 WILFRIED MULLENS MD PhD, PIETER MARTENS MD PhD
-
The Future of Durable Mechanical Circulatory Support: Emerging Technological Innovations and Considerations to Enable Evolution of the Field J. Card. Fail. (IF 6.0) Pub Date : 2024-02-29 Seraina A. Dual PhD, Jennifer Cowger MD MS, Ellen Roche PhD, Aditi Nayak MD MS
The field of durable mechanical circulatory support (MCS) has undergone an incredible evolution over the past few decades, resulting in significant improvements in longevity and quality of life for patients with advanced heart failure. Despite these successes, substantial opportunities for further improvements remain, including in pump design and ancillary technology, perioperative and postoperative
-
Patient Focus: A Prescription to Move. An Explanation of The Effectiveness of Lifestyle Interventions in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis J. Card. Fail. (IF 6.0) Pub Date : 2024-02-27 ANAS JAWAID MD, JENNIFER T. THIBODEAU MD MSCS
In this issue of the Journal of Cardiac Failure, Dr. Grace Walters and colleagues look at which lifestyle interventions in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) can best improve exercise tolerance, functional capacity, and overall quality of life ().
-
Settling the IRONy of Anemia in Heart Failure: Current Evidence and Future Directions J. Card. Fail. (IF 6.0) Pub Date : 2024-02-23 Adamantios Tsangaris, Andrew P. Ambrosy, Michael Tschida, Tamas Alexy
-
Safety indicators in the STRONG-HF trial from a methodological perspective J. Card. Fail. (IF 6.0) Pub Date : 2024-02-21 Xavier Rossello
-
Modes of Death in Patients with Cardiogenic Shock in the Cardiac Intensive Care Unit: A Report from the Critical Care Cardiology Trials Network J. Card. Fail. (IF 6.0) Pub Date : 2024-02-21 DAVID D. BERG MD MPH, SACHIT SINGAL MD, MICHAEL PALAZZOLO MS, VIVIAN M. BAIRD-ZARS MPH, FADEL BOFARRAG MD MPH, ERIN A. BOHULA MD DPhil, SUNIT-PREET CHAUDHRY MD, MARK W. DODSON MD PhD, DUSTIN HILLERSON MD, PATRICK R. LAWLER MD MPH, SHUANGBO LIU MD, CONNOR G. O'BRIEN MD, BARBARA A. PISANI MD, LEKHA RACHARLA DO, ROBERT O. ROSWELL MD, KEVIN S. SHAH MD, MICHAEL A. SOLOMON MD MBA, LAKSHMI SRIDHARAN MD, ANDREA
There are limited data on how patients with cardiogenic shock (CS) die. The Critical Care Cardiology Trials Network is a research network of cardiac intensive care units coordinated by the Thrombolysis In Myocardial Infarction (TIMI) Study Group (Boston, MA). Using standardized definitions, site investigators classified direct modes of in-hospital death for CS admissions (October 2021 to September
-
Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2i) Following FDA Approval for Heart Failure with Preserved and Mildly Reduced Ejection Fraction J. Card. Fail. (IF 6.0) Pub Date : 2024-02-16 Trejeeve Martyn, Joshua Saef, Agam Bansal, Kathryn A. Martinez, Hunter Block-Beach, Jessica Hohman, Samir R. Kapadia, Milind Y. Desai, Jerry D. Estep, Nancy M. Albert, Randall C. Starling, W.H. Wilson Tang
-
Outcomes of Patients with Cardiogenic Shock in Hub and Spoke Centers: The importance of Protocol Standardization at a Network Level J. Card. Fail. (IF 6.0) Pub Date : 2024-02-16 Carlos L. Alviar, Sylvie Hall, Alexandre Mebazaa
-
Genetic Interleukin-6 Receptor Variant Is Not Associated With Rejection and Mortality After Heart Transplantation J. Card. Fail. (IF 6.0) Pub Date : 2024-02-16 KAUSHIK AMANCHERLA MD, KELLY H. SCHLENDORF MD MHS, CAITLYN VLASSCHAERT MD MSc, BRANDON D. LOWERY, QUINN S. WELLS MD MSCI, SARAH B. SEE PhD, EMMANUEL ZORN PhD, PAOLO C. COLOMBO MD, MUREDACH P. REILLY MBBCh MSCE, JOANN LINDENFELD MD, NIR URIEL MD MSc, RAVI V. SHAH MD, JANE E. FREEDMAN MD, JAVID MOSLEHI MD, ALEX G. BICK MD PhD, KEVIN CLERKIN MD MSc
-
Low levels of selenoprotein P associate with cognitive impairment in patients hospitalized for heart failure J. Card. Fail. (IF 6.0) Pub Date : 2024-02-15 Amra Jujić, John Molvin, Erik D. Nilsson, Hannes Holm Isholt, Anna Dieden, Johan Korduner, Amir Zaghi, Zainu Nezami, Andreas Bergmann, Lutz Schomburg, Martin Magnusson
[Display omitted]
-
The Growing Tools in the Toolbox for Heart Transplantation J. Card. Fail. (IF 6.0) Pub Date : 2024-02-15 Gene Kim, Maria Giovanna Trivieri
-
-
-
A Board of Our Own: The New American Board for Cardiovascular Medicine J. Card. Fail. (IF 6.0) Pub Date : 2024-02-13 JAMES C. FANG
-
The Heart as a Reminder for Oneness J. Card. Fail. (IF 6.0) Pub Date : 2024-02-13 ANURADHA LALA, MEREDITH T. HURT, ROBERT J. MENTZ
-
-
Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF J. Card. Fail. (IF 6.0) Pub Date : 2024-02-01 ELISSA DRIGGIN MD MS, PARAG GOYAL MD MSC
Abstract not available
-
Patient Focus: Sodium-Glucose Cotransporter-2 Inhibitor Rates for Patients with Heart Failure in the Veterans Affairs Health System. We Need to Move the Needle! An explanation of “Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Hospitalized Patients with Heart Failure: Insights from the Veterans Affairs Healthcare System” J. Card. Fail. (IF 6.0) Pub Date : 2024-01-27 Nicholas S. Hendren, Jennifer T. Thibodeau
Abstract not available
-
Uptake of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure: insights from the veterans affairs healthcare system J. Card. Fail. (IF 6.0) Pub Date : 2024-01-26 Anubodh S. Varshney, Jamie Calma, Neil M. Kalwani, Stephanie Hsiao, Karim Sallam, Fang Cao, Natasha Din, Jessica Schirmer, Ankeet S. Bhatt, Andrew P. Ambrosy, Paul Heidenreich, Alexander T. Sandhu
Background The use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in Veteran Affairs (VA) patients hospitalized with heart failure (HF) has not been previously reported. Methods VA electronic health record data were used to identify patients hospitalized for HF (primary or secondary diagnosis) from 01/2019-11/2022. Patients with SGLT2i allergy, advanced/end-stage chronic kidney disease (CKD)
-
A Single Center Analysis of Palliative Care Clinician Contact Following Declination from Advanced Heart Failure Therapy J. Card. Fail. (IF 6.0) Pub Date : 2024-01-26 Kolby Johnson, Leigh Vaughan, Jennifer Dulin, Elizabeth Higgins, Abigail Southard
Abstract not available
-
Advanced Heart Failure and Transplant Cardiology as a New Subspecialty in Latin America: Challenges and Opportunities Based on a Brazilian Survey Study J. Card. Fail. (IF 6.0) Pub Date : 2024-01-22 Rafaela Vebber Bisol, Nadine Clausell, Jefferson L. Vieira, Fernando Bacal, Renato D. Lopes, Livia Adams Goldraich
Abstract not available
-
With Great Data Come Great Responsibilities: The Cardiac Amyloidosis Registry Study J. Card. Fail. (IF 6.0) Pub Date : 2024-01-18 Jennifer Maning, Sanjiv J. Shah, Ravi B. Patel
Abstract not available
-
Blood pressure response and symptoms during active standing test among hospitalized and outpatients with heart failure: results from the GRAVITY-HF prospective observational cohort study J. Card. Fail. (IF 6.0) Pub Date : 2024-01-17 Anzhela Soloveva, Darya Fedorova, Marat Fudim, Nadezhda Vinogradova, Alena Chemodanova, Anastasia Kozlova, Igor Fomin, Mariya Skuratova, Natalia Shneidmiller, Galina Golovina, Elena Kosmacheva, Ekaterina Gubareva, Marina Teterina, Elena Godunko, Anna Chesnikova, Igor Okunev, Vasily Kashtalap, Mariia Kuznetsova, Olga Dzhioeva, Kristina Kopeva, Svetlana Villevalde
-
Left Atrial Myopathy As Assessed On Echocardiography Is Predictive Of Atrial Fibrillation Recurrence After Coronary Artery Bypass Surgery J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Al-Ameen Oredegbe, Jeanwoo Yoo, Kyle Miller, Hafiza Waqar, John Tremblay, Zachary Kimball, George Tawfellos, Evan Adelstein, Mikhail Torosoff
Background Atrial fibrillation (AF) and atrial flutter (AFL) are common after coronary artery bypass (CABG) surgery and are associated with significant morbidity. Assessed with echocardiogram left atrial function has been shown in various studies to be a marker of cardiovascular risk. Effects of left atrial size and function on post-CABG acute and recurrent atrial fibrillation were not well investigated
-
A Reason to be Positive: Early Cardiac Allograft Vasculopathy and Acute Rejection in Recipients of HCV+ Donor Hearts J. Card. Fail. (IF 6.0) Pub Date : 2024-01-11 Laura DiChiacchio, Andrew R Higgins
Abstract not available
-
Relationship Between Healthcare Team Segregation & Receipt Of Care By A Cardiologist According To Patient Race J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Janina Quintero Bisono, Delancee Trabue, Ryan Yee, Shannon Knapp, Francesca Williamson, Adedoyin Johnson, Stephen Watty, Natalie Pool, Megan Hebdon, Wanda Moore, Ekoh Yankah, Nneamaka Ezema, Nia Kimbrough, Jhonnie Washington, Karen Lightbourne, Brownsyne Tucker Edmonds, Quinn Capers, David Brown, Denee Johnson, Jalynn Evans, Khadijah Breathett
Background Segregation index (SI) has been used to measure the degree of segregation between racial groups within specific geographic areas and has been associated with worse health outcomes. However, the relationship between SI within healthcare teams (degree of heterogeneity between teams that care for Black patients versus White patients, also called dissimilarity index) and cardiovascular care
-
Revealing The Enigma Of Cardiac Sarcoidosis: The Crucial Significance Of Advanced Imaging Modalities- A Case Report J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Resha Khanal, Sharad Oli, Luis Afonso, Lobelia Samavati
Background Cardiac sarcoidosis (CS) can present with various symptoms including heart failure, arrhythmias or sudden cardiac death. Due to this diverse presentation, the management can be challenging. We present a case of CS illuminating the significance of multimodality imaging techniques. Case 26-year male with biopsy proven pulmonary sarcoidosis presented with palpitation and lightheadedness. EKG
-
Weight Loss Management By A Pharmacist To Overcome Obesity As A Barrier To Surgical Advanced Heart Failure Interventions J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Amy D. Brewster, Samantha Bacon, Dmitry Yaranov
Introduction The prevalence of obesity has risen significantly in the Unites States since 2000, from 30.5% to 41.9% with a rise in severe obesity as well. Patients with obesity struggle with a variety of comorbid conditions including heart disease. Unfortunately, obesity places candidates for advanced heart failure (AHF) therapies at higher risk for complications and post intervention mortality. AACE/ACE
-
Outpatient Navigation Increases Enrollment In Serious Illness Services For Outpatients With Chronic Heart Failure J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Joy Duer, Juhi Saxena, Hongmei Yang, Emily Bowers, Bridget Hiller, John Barkley, Priyesh Patel
Intro Heart failure is a common and costly medical illness with poor prognosis, with as low as 25% survival rate at 5 years post-index hospitalization. Many serious illness services (SIS) such as clinic-based palliative care, home based palliative care, hospice, and nurse care management have been developed to improve quality of life and reduce acute care utilization. However, these services remain
-
Impact Of Disease Management Interventions On Heart Failure Preserved Ejection Fraction In An Acute Setting J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Susan Bionat, Miriam delaflor Santa Ana
Background Heart failure with preserved EF ( HFpEF) is a condition common in the older population related to multiple co morbidities. According to “The Get With The Guidelines-Heart Failure “registry which was linked to Medicare administrative data (2006 - 2014) data that hospitalized patients with HFpEFa are ≥65 years of age. The final cohort included 53,065 patients with HFpEF and the overall 30-day
-
Patients With Amyloidosis Undergoing Transcatheter Edge-to-edge Repair Have Greater Risk Of Mortality And Higher Resource Utilization, Nation-wide Study J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Leonid Khokhlov, Fatima Hussain, Mehnaaz Ali, Angel Mena, Amr Aboelnasr, Sila Mateo-Faxas, Amin Eshghabadi, Mohamad Hijazi, Kenan Rahima, Sindhu Kishore, Kamal Shemisa, Mohammed Al-Amoodi
Background Transcatheter edge-to-edge repair (TEER) is a minimally invasive approach in the treatment of primary mitral regurgitation. Amyloidosis is a rare condition caused by misfolded protein fibrils deposition in the extracellular space. There is limited evidence of clinical outcomes in patients hospitalized for TEER and affected by amyloidosis. Hence, we sought to investigate this population.
-
Impact Of Covid-19 Pandemic And Expansion Of Telemedicine On Palliative Care Utilization Among Patients Admitted With Heart Failure J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Aleesha Kainat, Bradley Very, Ahmet Sezer, Floyd Thoma, Gavin Hickey
Introduction The 2022 ACC/AHA/HFSA guidelines recommend integration of palliative care (PC) in heart failure (HF) management. Despite these recommendations, palliative care (PC) utilization remains suboptimal. It remains unclear how the evolution of telemedicine during the COVID-19 pandemic impacted PC delivery for the HF population. We sought to evaluate trends in telemedicine and in-person PC visits
-
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results from the GALACTIC-HF study J. Card. Fail. (IF 6.0) Pub Date : 2024-01-11 G. Michael Felker, Scott D. Solomon, Marco Metra, John J.V. McMurray, Rafael Diaz, Brian Claggett, David E. Lanfear, Hans Vandekerckhove, Tor Biering-Sørensen, Renato D. Lopes, Alexandra Arias-Mendoza, Shin-ichi Momomura, Ramon Corbalan, Felix J.A. Ramires, Faiez Zannad, Stephen B. Heitner, Punag H. Divanji, Stuart Kupfer, Fady I. Malik, John R. Teerlink
Background Omecamtiv mecarbil improves outcomes in patients with heart failure and reduced ejection fraction (HFrEF). We examined the relationship between baseline troponin, change in troponin over time, and the treatment effect of omecamtiv mecarbil in patients enrolled in the Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF) trial
-
The Veterans Affairs’ Dashboard Confessional: Vindication of the VA HF Dashboard J. Card. Fail. (IF 6.0) Pub Date : 2024-01-11 Melissa Lyle, Mark N. Belkin
Abstract not available
-
Outcomes Of Donor Circulatory Death Heart Transplantation In Recipients With Durable Left Ventricular Assist Device J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Edwin Grajeda, Aris Karatasakis, Lorenzo Braghieri, Song Li, Claudius Mahr, Claudio Bravo
Introduction Donation after circulatory death (DCD) is gaining interest as a strategy to increase the donor pool. In the old allocation system, patients supported with durable LVAD who had undergone a heart transplant had similar outcomes compared to transplant patients without this device when receiving a donation after brain death (BD) organ. Whether patients with LVAD have similar outcomes when
-
Efficacy Of Intravenous Iron In Patients With Heart Failure With Reduced Ejection Fraction And Iron Deficiency: A Systematic Review And Meta-analysis Of Randomized Control Trials J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Andrew Sephien, Denisse Camille Dayto, Tea Reljic, Xavier Prida, Joanna M. Joly, Matthew Tavares, Jason N. Katz, Ambuj Kumar
Background The 2022 AHA/ACC/HFSA Guideline for Management of Heart Failure provides a 2A (LOEB-R) recommendation for intravenous (IV) iron in patients with heart failure with reduced ejection (HFrEF) and iron deficiency (ID). However, the findings from randomized control trials (RCT) are mixed. This systematic review of RCTs aims to provide an update and synthesize the evidence addressing the association
-
Cardiogenic Shock: An Unusual Presentation Of Hydralazine-induced Anca-associated Vasculitis J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Arnav Srivastava, Massiel E. Jimenez Artiles, Mostafa Elbanna, Mohammad Abu Sheikha, Vishal Parikh, Scott Feitell
Introduction ANCA-associated vasculitis (AAV) encompasses several overlapping syndromes such as GPA, MPA, and drug-induced vasculitis syndromes. Glomerulonephritis is the most common manifestation. Rarely, AAV can cause cardiogenic shock. Case presentation A 68-year-old female with a past medical history of hypertension on Hydralazine (for over 2 years), Metoprolol, and Clonidine, COPD, and atrial
-
Evaluation Of The H2FPEF And HFA-PEFF Diagnostic Scores In Obese Hemodynamically Confirmed HFpEF J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Soumya Vungarala, Vivek Jani, Joban Vaishnav, Virginia Hahn, David Kass, Kavita Sharma
Background Heart failure with preserved ejection fraction (HFpEF) was once predominantly a disease of older patients with hypertension and left ventricular hypertrophy. However, the prevalent phenotype has markedly changed to one of obesity and metabolic syndrome. Scoring algorithms derived from prior common HFpEF phenotypes, including the H2FPEF and HFA-PEFF scores, have yet to be evaluated in a predominantly
-
Does Duration Of Gdmt Up-titration Affect The Percentage Of Hfimpef Attainment? J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Hassan Dehaini, Jasmin Ortiz, Megan Valante, Kathir Balakumaran
Introduction Heart failure with improved ejection fraction (HFimpEF) is defined as heart failure with previous LVEF ≤40% and a follow-up LVEF >40%. Although it does not reflect full myocardial recovery, HFimpEF is a marker of GDMT's effectiveness. Not all patients, however, are able to attain HFimpEF, and the factors behind the development of HFimpEF remain under investigation. One of those factors
-
JCF Heart Failure Year-In-Review 2023… Shaping the Future of Heart Failure J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 QUENTIN R. YOUMANS, ANURADHA LALA, ROBERT J. MENTZ
Abstract not available
-
Corrigendum to ‘The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support’ J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09
Abstract not available
-
Proteomic Associations Of N-terminal-pro Hormone Bnp In Heart Failure With Preserved Ejection Fraction In Two Cohorts J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Joe David Azzo, Marie-Joe Dib, Lei Zhao, Zhaoqing Wang, Christina Ebert, Oday Salman, Sushrima Gan, Payman Zamani, Jordana (Jordy) Cohen, Vanessa van Empel, Mark Richards, Robert Doughty, Ali Javaheri, Peter Schafer, Dietmar Seiffert, Francisco Ramirez-Valle, David Gordon, Thomas Cappola, Julio Chirinos
Background N-terminal-pro natriuretic peptide (NT-proBNP) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even among patients with increased left ventricular filling pressures. NT-proBNP levels are prognostic in HFpEF, and NT-proBNP levels have been used as an inclusion criterion for several recent landmark randomized clinical trials but the underlying biologic
-
Isovolumic Contraction Velocity In Heart Failure With Reduced Ejection Fraction And Effect Of Sacubitril/valsartan: The PROVE-HF Study J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Alaa M. Omar, Sean Murphy, Michael Felker, Ileana Piña, Javed Butler, Yuxi Liu, Reza Mohebi, Jonathan Ward, Kristin Williamson, Scott D. Solomon, James Januzzi, Johannita Contreras
Introduction The load dependent left ventricular ejection fraction (LVEF) has been the cornerstone of systolic function assessment, yet its inherent limitations highlight the need for alternative prognostic measures of myocardial remodeling. We assessed the value of tissue-Doppler derived mitral annular isovolumic contraction velocity (ICV), a load independent measure of systolic function, in prediction
-
Post-exercise Oxygen Uptake Recovery Delay In Individuals With Left Ventricular Assist Device J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Charounipha Soydara, Ilya Giverts, Joseph Campain, Katherine Milley, Janice M. Camuso, Tara Logan, Alexandra E. Anthony, Eriberto Michel, Asishana A. Osho, David A. D'Alessandro, Erin Coglianese, Corrine Y. Jurgens, Van-Khue Ton, Gregory D. Lewis
Background Cardiopulmonary exercise testing (CPET) enables objective measurement multi-organ function during exercise in patients with heart failure (HF). Post-exercise oxygen uptake recovery delay (VO2RD), a non-invasive CPET metric, is the time when VO2 falls permanently below peak VO2 after loaded exercise. VO2RD reflects the inadequacy of cardiac output augmentation during incremental exercise
-
HERMES: Effects Of Ziltivekimab Versus Placebo On Morbidity And Mortality In Patients With Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Mark Petrie, Barry Borlaug, Kristine Buchholtz, Anique Ducharme, Anders Hvelplund, Carolyn Lam Su Ping, Guiomar Mendieta, Søren Østergaard Hardt-Lindberg, Adriaan A. Voors, Paul M. Ridker
Background - Inflammation is a central pathophysiological process in heart failure with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF). Il-6, a pro-inflammatory cytokine, is an independent risk factor for adverse outcomes in HFpEF and HFmrEF. Ziltivekimab is a human monoclonal antibody directed against IL-6. Whether or not anti-inflammatory therapy with the anti-IL-6 therapy, ziltivekimab
-
Transcatheter Aortic Valve Replacement Is A Viable Option For Aortic Stenosis Patients Presenting With Cardiogenic Shock J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Rohit Masih, Ina Lico, Jawad Haider, Robert Hagberg, Mohiuddin Cheema, Sabet Hashim, Raymond McKay
INTRODUCTION Prior studies have demonstrated that cardiogenic shock (CS) in patients with concomitant severe aortic stenosis (AS) is associated with a >40% incidence of in-hospital mortality when treated with medical therapy alone. There have been limited prior reports on the outcomes of critically ill patients with severe AS and CS who are treated with transcatheter aortic valve replacement (TAVR)
-
Saving Hearts In Rural West Texas: Impact Of Critical Care Access On Mortality Rates J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Rami Al-Ayyubi, Laura Gonzalez-Reyes, Andres Mata, Divya Parepalli, Muhammad Qudrat Ullah, Aimen Dar, Raghavendra Sanivarapu
Introduction The critical access hospital (CAH) designation program was created in 1997 by the US congress with the purpose of reducing the financial vulnerability of rural hospitals and improving the access to healthcare by keeping fundamental services in rural communities. Hypothesis Heart failure (HF) patients residing in rural counties of West Texas (WT) will have better outcomes in terms of mortality
-
Treatment Effects Of Empagliflozin In Hospitalized Heart Failure Patients Across The Range Of Left Ventricular Ejection Fraction - Results From The EMPULSE Trial J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Jasper Tromp, Mikhail Kosiborod, Christiane Angermann, Sean Collins, John Teerlink, Piotr Ponikowski, Jan Biegus, Joao Pedro Ferreira, Michael Nassif, Mitchell Psotka, Martina Brückmann, Jonathan Blatchford, Dominik Steubl, Adriaan Voors
Background The EMPULSE trial recently showed that the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) (SGLT2i) improved clinical outcomes of patients who were hospitalized for acute heart failure. In this post-hoc analysis we studied whether the effects were consistent according to the range of left ventricular ejection fraction (LVEF). Methods EMPULSE (EMPagliflozin in patients
-
Clinical Utility Of An AI-Based Model For Detection Of Heart Failure With Preserved Ejection Fraction Using Decision Curve Analysis J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Ross Upton, Ashley P. Akerman, Mihaela Porumb, Christopher G. Scott, Arian Beqiri, Agisilaos Chartsias, Alexander Ryu, William Hawkes, Geoffrey Huntley, Ayana Arystan, Garvan Kane, Sorin Pislaru, Francisco Lopez-Jimenez, Rizwan Sarwar, Jamie O'Driscoll, Paul Leeson, Gary Woodward, Patricia A. Pellikka
Background Detection of heart failure with preserved ejection fraction (HFpEF) remains challenging due to indeterminate imaging outputs and discordant clinical features. Existing guidelines and clinical algorithms often produce non-diagnostic outcomes, especially in complicated cases. To address this, we developed an artificial intelligence (AI) model to analyze a single echocardiographic video clip
-
Implications Of Dosing IV Loop Diuretic Relative To Home Loop Diuretic In Hospitalized Patients With Decompensated Heart Failure J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Michael T. Kimbrell, Jaskeerat Gulati, Lin Zhong, Yiqing Wang, Donghan Yang, Bethany Roehm, Susan Hedayati, Mary Jane Farr, Nicholas Hendren, Mark Drazner, Wai Hong Tang, Justin Grodin
Introduction Intravenous loop diuretics (IVLDs) are crucial to achieve clinical compensation in acute decompensated heart failure (ADHF). The Heart Failure Clinical Research Network studies have proposed dosing IV loop diuretics based on home loop diuretic (HLD) dosing and touted 2.5x dosing may not significantly affect kidney function. However, the risk-benefit assessment of these strategies in real-world
-
Real-world Experience Of Adverse Events And Modes Of Failure Related To The New Impella 5.5 - A Retrospective Analysis From Manufacturer And User Facility Device Experience Database J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Kripa Rajak, Anupam Halder, Aslan Amirian, Resha Khanal, Anas Atrash, Navitha Ramesh, Rohan Goswami
Introduction Impella 5.5 with Smart Assist is the newest heart pump that has received U.S. Food and Drug Administration (FDA) pre-market approval in 2019 for safety and efficacy in the therapy of cardiogenic shock for up to 14 days at limited centers in the United States. Impella consists of several different models that vary in caliber, insertion technique, and maximum hemodynamic support capabilities
-
Synchronized Diaphragmatic Stimulation As A Potential Outpatient Implant Procedure For HfrEF Therapy J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Georg Becker, Tamaz Shaburishvili, Darejan Chiabrishvili, Beka Oniani, Giorgi Shaishmelashvili, Marat Fudim, Michael Mirro, Lee Goldberg
Background Synchronized diaphragmatic stimulation (SDS) transiently modulates intrathoracic pressure synchronized to the cardiac cycle thereby impacting pericardial restraint, cardiac preload and afterload leading to improvements in heart failure status, including exercise tolerance, quality of life and functional cardiac measures. Symptomatic HFrEF patients on optimal GDMT with no evidence of ventricular
-
Percutaneous Stenting Of The Bend Relief And Proximal Segment Outflow Graft Of Durable Left Ventricular Assisted Device J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Rakushumimarika Harada, Srinivasa Potluri, Thuy Pham, David Rawitscher, Nitin Kabra, Gregory Milligan, Timothy George, Aasim Afzal
Introduction Outflow graft occlusion due to extrinsic compression within the bend relief is a rare but known complication of a durable left ventricular assisted device (LVAD) Heartmate 3. The occlusion occurring at the proximal segment of the graft or bend relief can be challenging to correct given its location and proximity to the pump. Herein, we present a case of occlusion in the bend relief and
-
Disparities In Biomarkers And Cardiac Remodeling In African American Patients Presenting With Transthyretin Cardiac Amyloidosis J. Card. Fail. (IF 6.0) Pub Date : 2024-01-09 Joyce Ngouchet Nouhossi, Vien Truong, Karolina M. Zareba, Orlando Simonetti, Amit R. Patel, Jai Singh, Cristiane Singulane, Akash Goyal, Nitasha Sarswat, Bryan Smith, Jeremy A. Slivnick
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common cause of heart failure caused by deposition of transthyretin fibrils in the myocardium. ATTR-CM remains underrecognized and underdiagnosed, especially in African American (AA) populations. As a result, patients often present at an advanced stage, and little is known about racial differences in presentation or outcomes. Accordingly